ALNY

Alnylam Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

438.930

+3.83(0.880%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

439.360

Open

435.100

VWAP

434.05

Vol

901.28K

Mkt Cap

57.53B

Low

427.660

Amount

391.20M

EV/EBITDA(TTM)

Total Shares

126.49M

55.70B

EV/OCF(TTM)

P/S(TTM)

23.09

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

1.14B

+91.46%

1.20B

+101.95%

942.70M

+88.19%

Estimates Revision

The market is revising Upward the revenue expectations for Alnylam Pharmaceuticals, Inc. (ALNY) for FY2025, with the revenue forecasts being adjusted by 20.98% over the past three months. During the same period, the stock price has changed by 62.45%.

Revenue Estimates for FY2025

Revise Upward

+20.98%

In Past 3 Month

Stock Price

Go Up

+62.45%

In Past 3 Month

27 Analyst Rating

-1.53% Downside

Wall Street analysts forecast ALNY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALNY is 432.21 USD with a low forecast of 290.00 USD and a high forecast of 550.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

21 Buy

6 Hold

0 Sell

Strong Buy

-1.53% Downside

Current: 438.930

Low

290.00

Averages

432.21

High

550.00

-1.53% Downside

Current: 438.930

Low

290.00

Averages

432.21

High

550.00

H.C. Wainwright

Buy

upgrade

$500 -> $580

2025-08-07

New

Reason

H.C. Wainwright

Price Target

$500 -> $580

2025-08-07

New

upgrade

Buy

Reason

H.C. Wainwright raised the firm's price target on Alnylam to $580 from $500 and keeps a Buy rating on the shares. The firm says the company's strong commercial execution and pipeline progress drove upward revisions to its 2025 guidance.

H.C. Wainwright

Patrick Trucchio

maintain

$500 -> $570

2025-08-07

New

Reason

H.C. Wainwright

Patrick Trucchio

Price Target

$500 -> $570

2025-08-07

New

maintain

Reason

H.C. Wainwright analyst Patrick Trucchio raised the firm's price target on Alnylam to $570 from $500 and keeps a Buy rating on the shares. The firm says the company's strong commercial execution and pipeline progress drove upward revisions to its 2025 guidance.

JPMorgan

NULL -> Overweight

maintain

$348 -> $475

2025-08-06

New

Reason

JPMorgan

Price Target

$348 -> $475

2025-08-06

New

maintain

NULL -> Overweight

Reason

JPMorgan raised the firm's price target on Alnylam to $475 from $348 and keeps an Overweight rating on the shares. The company reported an "exceptionally strong Q2 and guidance increase, the analyst tells investors in a research note. The firm continues to see a "healthy launch" ahead for Amvuttra.

Oppenheimer

Perform -> Outperform

upgrade

$490

2025-08-04

Reason

Oppenheimer

Price Target

$490

2025-08-04

upgrade

Perform -> Outperform

Reason

Oppenheimer upgraded Alnylam to Outperform from Perform with a $490 price target.

Wolfe Research

Underperform -> Peer Perform

upgrade

$368

2025-08-04

Reason

Wolfe Research

Price Target

$368

2025-08-04

upgrade

Underperform -> Peer Perform

Reason

Wolfe Research upgraded Alnylam to Peer Perform from Underperform and removed the firm's prior $368 price target. The company "surprised" with its ability to find new patients, says the analyst, who adds that the stock's "lofty valuation still bothers us," but the firm is "owning up to our mistaken Underperform rating," noting that shares have performed well since November of 2024.

Oppenheimer

Leland Gershell

Perform -> Outperform

upgrade

$490

2025-08-04

Reason

Oppenheimer

Leland Gershell

Price Target

$490

2025-08-04

upgrade

Perform -> Outperform

Reason

Oppenheimer analyst Leland Gershell upgraded Alnylam to Outperform from Perform with a $490 price target. The first full quarter of Amvuttra sales in transthyretin amyloid cardiomyopathy sales beat by a sizable margin as Alnylam secured payer agreements much faster than anticipated, the analyst tells investors in a research note. The firm says management commentary on the earnings was favorable on all aspects of the launch. Oppenheimer expects further share outperformance as Amvuttra's commercialization for ATTR-CM continues and Street estimates move up.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Alnylam Pharmaceuticals Inc (ALNY.O) is 123.78, compared to its 5-year average forward P/E of -56.59. For a more detailed relative valuation and DCF analysis to assess Alnylam Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-56.59

Current PE

123.78

Overvalued PE

23.85

Undervalued PE

-137.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-7419.64

Current EV/EBITDA

69.58

Overvalued EV/EBITDA

51044.70

Undervalued EV/EBITDA

-65883.98

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

16.35

Current PS

12.62

Overvalued PS

20.76

Undervalued PS

11.95